9 results
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
(GCA) • Takayasu's ... Polyangiitis (GPA ... Sources: GCA ... #Treatment #ACR2021 ... #Guidelines #algorithm
2021 ACR/VF Guidelines for Management of Giant Cell Arteritis (GCA)

#GiantCell #Arteritis #GCA #ACR2021 #Management #rheumatology #algorithm
2021 ACR/VF Guidelines ... (GCA) #GiantCell ... #Arteritis #GCA ... #ACR2021 #Management ... #rheumatology #
2021 ACR/VF Guidelines for Management of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

#Granulomatosis #Polyangiitis #GPA
2021 ACR/VF Guidelines ... Polyangiitis (GPA ... #Polyangiitis #GPA ... #ACR2021 #Management ... #rheumatology #
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Polyangiitis (GPA ... #Polyangiitis #GPA ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
(GCA) - Vasculitis ... Management Algorithm ... #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Algorithm - ACR ... /VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
Algorithm - ACR ... /VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Takayasu's Arteritis (TAK) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active TAK not on
Takayasu's Arteritis ... Algorithm - ACR ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Treatment of giant cell arteritis (GCA)

1st Line Strategy - GC 0.7 mg/kg/day, except for:
 • Aortitis
(GCA) 1st Line ... #GCA #Treatment ... #Management #Relapses ... #Indications #rheumatology ... #2ndline